We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
lennox-Gastaut syndrome: an updateon treatment.
- Authors
Carmant, Lionel; Whiting, Sharon
- Abstract
Lennox-Gastaut syndrome (LGS) is a severe epileptic encephalopathy. Few current treatment options are effective in improving seizure control. This paper reviews the available treatments of LGS and discusses a new option in Canada, rufinamide. It is a wide spectrum anticonvulsant, approved in a number of countries for the treatment of LGS. In a randomized controlled trial in the LGS population, adjunctive rufinamide therapy has been shown to offer significantly greater reduction in total seizure frequency and tonic-atonic seizure frequency in comparison to placebo. Efficacy has been assessed over three years and appears to be sustained. Most adverse events were cognitive (e.g. somnolence) or gastrointestinal in nature and in many cases transient or mild. based on the efficacy and safety data on rufinamide obtained to date, this medication will provide additional benefits to patients with LGS in Canada and is an important consideration for our patients in the adjunctive treatment setting.
- Publication
The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 2012, Vol 39, Issue 6, p702
- ISSN
0317-1671
- Publication type
Journal Article
- DOI
10.1017/s0317167100015535